Because MCR agonists have been shown to suppress inflammation and modulate autoimmunity [17, 18, 37–39], the present study was conducted in an animal model of RA to evaluate the efficacy of RCI as monotherapy or as adjuvant therapy with the anti-TNF agent ETN. This evidence concerns the gene NR3C2 and rheumatoid arthritis.